• Interaction Score: 0.79

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Evidence Type Actionable
    Approval Status Preclinical - Cell line xenograft
    Response Type predicted – sensitive

    PMIDs:
    27573426


    Sources:
    JAX-CKB

  • Interaction Score: 0.75

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy BYL719 + MEK162
    Indication/Tumor Type acute myeloid leukemia
    Response Type sensitive

  • Interaction Score: 0.62

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Drug family EGFR mAb inhibitor
    Alteration NRAS:.
    Indication/Tumor Type colorectal cancer

  • Interaction Score: 0.59

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type melanoma
    Response Type sensitive
    Approval Status Preclinical

    PMIDs:
    22351686


    Sources:
    JAX-CKB

  • Interaction Score: 0.59

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type melanoma
    Response Type sensitive
    Approval Status Preclinical - Cell culture

    PMIDs:
    26267534


    Sources:
    JAX-CKB

  • Interaction Score: 0.47

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26095797


    Sources:
    CIViC

  • Interaction Score: 0.47

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type non-small cell lung carcinoma
    Response Type resistant
    Approval Status Preclinical

    PMIDs:
    25870145


    Sources:
    JAX-CKB

  • Interaction Score: 0.47

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type Advanced Solid Tumor
    Response Type sensitive
    Approval Status Preclinical

    PMIDs:
    22460902


    Sources:
    JAX-CKB

  • Interaction Score: 0.46

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Response Type no benefit
    Indication/Tumor Type melanoma
    Response Type sensitive

  • Interaction Score: 0.43

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Drug family BRAF inhibitor
    Alteration NRAS:.
    Indication/Tumor Type melanoma

  • Interaction Score: 0.39

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Approval Status Preclinical
    Indication/Tumor Type melanoma
    Response Type decreased response

    PMIDs:
    26343583


    Sources:
    JAX-CKB

  • Interaction Score: 0.39

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Novel drug target Novel Target
    Trial Name Reolysin

    PMIDs:
    None found


    Sources:
    TdgClinicalTrial

  • Interaction Score: 0.36

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type melanoma
    Response Type resistant
    Approval Status Preclinical - Cell line xenograft


    Sources:
    JAX-CKB

  • Interaction Score: 0.34

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type melanoma
    Response Type sensitive
    Approval Status Preclinical

    PMIDs:
    23039341


    Sources:
    JAX-CKB

  • Interaction Score: 0.34

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Cetuximab + FOLFOX
    Indication/Tumor Type colorectal cancer
    Response Type predicted – sensitive

  • Interaction Score: 0.31

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Trametinib + Dabrafenib
    Indication/Tumor Type melanoma
    Response Type sensitive

  • Interaction Score: 0.3

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type colorectal cancer
    Response Type predicted – sensitive
    Approval Status Preclinical - Cell culture

    PMIDs:
    26439693


    Sources:
    JAX-CKB

  • Interaction Score: 0.3

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Binimetinib + Ribociclib
    Evidence Type Actionable
    Approval Status Phase Ib/II

    PMIDs:
    26987942


    Sources:
    JAX-CKB CIViC OncoKB

  • Interaction Score: 0.27

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type non-small cell lung carcinoma
    Response Type resistant
    Approval Status Phase I

  • Interaction Score: 0.26

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type acute myeloid leukemia
    Response Type sensitive
    Approval Status Preclinical

    PMIDs:
    26627013


    Sources:
    JAX-CKB

  • Interaction Score: 0.26

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Everolimus + Pimasertib
    Indication/Tumor Type non-small cell lung carcinoma
    Response Type sensitive

    PMIDs:
    23629727


    Sources:
    JAX-CKB

  • Interaction Score: 0.25

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type melanoma
    Response Type decreased response
    Approval Status Preclinical


    Sources:
    JAX-CKB CIViC

  • Interaction Score: 0.24

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type non-small cell lung carcinoma
    Response Type resistant
    Approval Status Preclinical

    PMIDs:
    25870145


    Sources:
    JAX-CKB

  • Interaction Score: 0.22

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type melanoma
    Response Type no benefit
    Approval Status Preclinical - Cell line xenograft

    PMIDs:
    27488531


    Sources:
    JAX-CKB

  • Interaction Score: 0.2

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type Advanced Solid Tumor
    Response Type predicted – sensitive
    Approval Status Phase I

    PMIDs:
    None found


    Sources:
    JAX-CKB

  • Interaction Score: 0.17

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type melanoma
    Response Type sensitive
    Approval Status Phase I

    PMIDs:
    26169970


    Sources:
    JAX-CKB

  • Interaction Score: 0.17

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    2498808


    Sources:
    NCI

  • Interaction Score: 0.17

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type melanoma
    Response Type sensitive
    Approval Status Phase I

    PMIDs:
    27217383


    Sources:
    JAX-CKB

  • Interaction Score: 0.17

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Details of the Assay for Interaction Measuring inhibition of farnesylation of NRAS by human farnesyltransferase
    Specific Action of the Ligand Inhibition
    Endogenous Drug? False

    PMIDs:
    None found


  • Interaction Score: 0.14

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type thyroid cancer
    Response Type sensitive
    Approval Status Preclinical - Cell culture

    PMIDs:
    21289267


    Sources:
    JAX-CKB

  • Interaction Score: 0.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type colorectal cancer
    Response Type resistant
    Approval Status Preclinical


    Sources:
    JAX-CKB

  • Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type non-small cell lung carcinoma
    Response Type decreased response
    Approval Status Preclinical


    Sources:
    JAX-CKB

  • Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Evidence Type Actionable
    Approval Status Preclinical - Cell culture
    Response Type sensitive


    Sources:
    JAX-CKB CIViC

  • Interaction Score: 0.11

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    1394224


    Sources:
    NCI

  • Interaction Score: 0.11

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Pembrolizumab + Trametinib
    Indication/Tumor Type melanoma
    Response Type no benefit

    PMIDs:
    28514312


    Sources:
    JAX-CKB

  • Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Binimetinib + BKM120
    Indication/Tumor Type melanoma
    Response Type sensitive

    PMIDs:
    27307593


    Sources:
    JAX-CKB

  • Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    OncoKB

  • Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Evidence Type Actionable
    Approval Status Preclinical
    Response Type sensitive

    PMIDs:
    24791855


    Sources:
    JAX-CKB

  • Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type melanoma
    Response Type sensitive
    Approval Status Preclinical - Cell culture


    Sources:
    JAX-CKB

  • Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Evidence Type Actionable
    Approval Status Preclinical - Cell line xenograft
    Response Type sensitive

    PMIDs:
    24569456


    Sources:
    JAX-CKB

  • Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25504439


    Sources:
    CIViC

  • Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22392911


    Sources:
    CIViC

  • Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Sorafenib;MEK inhibitor
    Drug family Pan-TK inhibitor;MEK inhibitor
    Alteration NRAS:.

    PMIDs:
    23629727


    Sources:
    JAX-CKB CGI

  • Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type non-small cell lung carcinoma
    Response Type resistant
    Approval Status Preclinical

    PMIDs:
    25870145


    Sources:
    JAX-CKB

  • Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21636554


    Sources:
    PharmGKB

  • Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21636554


    Sources:
    PharmGKB

  • Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21636554


    Sources:
    PharmGKB